• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Aclaris Therapeutics Inc.

    6/5/25 5:01:02 PM ET
    $ACRS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ACRS alert in real time by email
    S-8 1 tm2517064d1_s8.htm FORM S-8

     

    As filed with the U.S. Securities and Exchange Commission on June 5, 2025

     

    Registration No. 333-      

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

     

    ACLARIS THERAPEUTICS, INC.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   46-0571712
    (State or other jurisdiction of
    Incorporation or organization)
      (I.R.S. Employer
    Identification No.)

     

    701 Lee Road, Suite 103
    Wayne, PA 19087

    (Address of principal executive offices) (Zip code)

     

     

     

    Aclaris Therapeutics, Inc. 2025 Equity Incentive Plan

    (Full title of the plan)

     

     

     

    Neal Walker

    Chief Executive Officer

    Aclaris Therapeutics, Inc.

    701 Lee Road, Suite 103

    Wayne, PA 19087

    (484) 324-7933

    (Name and address of agent for service) (Telephone number, including area code, of agent for service)

     

    Copies to:

    Mark Ballantyne
    Cooley LLP
    11951 Freedom Drive
    Reston, VA 20190-5640
    (703) 456-8000
     
      Kevin Balthaser
    Chief Financial Officer
    Aclaris Therapeutics, Inc.
    701 Lee Road, Suite 103
    Wayne, PA 19087
    (484) 324-7933
     

     

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ¨ Accelerated filer ¨
    Non-accelerated filer x Smaller reporting company x
      Emerging growth company ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ¨

     

     

     

     

     

     

    EXPLANATORY NOTE

     

    This registration statement on Form S-8 (the “Registration Statement”) is being filed for the purpose of registering 25,532,993 shares of common stock of Aclaris Therapeutics, Inc. (the “Registrant”) that may be issued pursuant to the Aclaris Therapeutics, Inc. 2025 Equity Incentive Plan.

     

    PART I

     

    INFORMATION REQUIRED IN THE SECTION 10(A) PROSPECTUS

     

    In accordance with the instructional note to Part I of Form S-8 as promulgated by the Securities and Exchange Commission (the “Commission”), the information specified by Part I of Form S-8 has been omitted from this Registration Statement.

     

     

     

     

    PART II

     

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3. Incorporation of Documents by Reference.

     

    The following documents filed by the Registrant with the Commission are incorporated by reference into this Registration Statement:

     

    (a)The Registrant’s Annual Report on Form 10-K (File No. 001-37581) for the fiscal year ended December 31, 2024, filed with the Commission on February 27, 2025.

     

    (b)The Registrant’s Quarterly Report on Form 10-Q (File No. 001-37581) for the quarter ended March 31, 2025, filed with the Commission on May 8, 2025.

     

    (c)The Registrant’s Current Report on Form 8-K (File No. 001-37581) filed with the Commission on June 5, 2025.

     

    (d)The description of the Registrant’s common stock which is contained in a registration statement on Form 8-A filed on October 2, 2015 (File No. 001-37581) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), as updated by the description of the Registrant’s common stock contained in the Registrant’s Annual Report on Form 10-K (File No. 001-37581) for the fiscal year ended December 31, 2023, filed with the Commission on February 27, 2024, including any amendment or report filed for the purpose of updating such description.

     

    All other reports and documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act (other than Current Reports on Form 8-K or portions thereof furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits furnished on such form that relate to such items) on or after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part of this Registration Statement from the date of the filing of such reports and documents.

     

    Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed document that also is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

     

    Item 4. Description of Securities.

     

    Not applicable.

     

    Item 5. Interests of Named Experts and Counsel.

     

    Not applicable.

     

    Item 6. Indemnification of Directors and Officers.

     

    The Registrant is incorporated under the laws of the State of Delaware. Section 102 of the Delaware General Corporation Law (the “DGCL”) permits a corporation to eliminate the personal liability of directors of a corporation to the corporation or its stockholders for monetary damages for a breach of fiduciary duty as a director, except where the director breached his duty of loyalty, failed to act in good faith, engaged in intentional misconduct or knowingly violated a law, authorized the payment of a dividend or approved a stock repurchase in violation of Delaware corporate law or obtained an improper personal benefit.

     

    2

     

     

    Section 145 of the DGCL provides that a corporation has the power to indemnify a director, officer, employee or agent of the corporation and certain other persons serving at the request of the corporation in related capacities against expenses (including attorneys’ fees), judgments, fines and amounts paid in settlements actually and reasonably incurred by the person in connection with an action, suit or proceeding to which he is or is threatened to be made a party by reason of such position, if such person acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the corporation, and, in any criminal action or proceeding, had no reasonable cause to believe his or her conduct was unlawful, except that, in the case of actions brought by or in the right of the corporation, no indemnification shall be made with respect to any claim, issue or matter as to which such person shall have been adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery or other adjudicating court determines that, despite the adjudication of liability but in view of all of the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which the Court of Chancery or such other court shall deem proper.

     

    As permitted by the DGCL, the Registrant’s amended and restated certificate of incorporation and amended and restated bylaws provide that: (i) the Registrant is required to indemnify its directors to the fullest extent permitted by the DGCL; (ii) the Registrant may, in its discretion, indemnify its officers, employees and agents as set forth in the DGCL; (iii) the Registrant is required, upon satisfaction of certain conditions, to advance all expenses incurred by its directors in connection with certain legal proceedings; (iv) the rights conferred in the bylaws are not exclusive; and (v) the Registrant is authorized to enter into indemnification agreements with its directors, officers, employees and agents.

     

    The Registrant has entered into agreements with its directors and executive officers that require the Registrant to indemnify them against expenses, judgments, fines, settlements and other amounts that any such person becomes legally obligated to pay (including with respect to a derivative action) in connection with any proceeding, whether actual or threatened, to which such person may be made a party by reason of the fact that such person is or was a director of the Registrant or any of its affiliates, provided such person acted in good faith and in a manner such person reasonably believed to be in, or not opposed to, the Registrant’s best interests. The indemnification agreements also set forth certain procedures that will apply in the event of a claim for indemnification thereunder. At present, no litigation or proceeding is pending that involves any of the Registrant’s directors or officers regarding which indemnification is sought, nor is the Registrant aware of any threatened litigation that may result in claims for indemnification.

     

    The Registrant maintains a directors’ and officers’ liability insurance policy. The policy insures directors and officers against unindemnified losses arising from certain wrongful acts in their capacities as directors and officers and reimburses the Registrant for those losses for which it has lawfully indemnified the directors and officers. The policy contains various exclusions.

     

    Item 7. Exemption from Registration Claimed.

     

    Not applicable.

     

    Item 8. Exhibits

     

        Incorporated by Reference
    Exhibit
    Number
    Description Schedule
    Form
    File
    Number
    Exhibit Filing Date
    4.1 Amended and Restated Certificate of Incorporation of the Registrant. 8-K 001-37581 3.1 10/13/2015
    4.2 Certificate of Amendment to Amended and Restated Certificate of Incorporation of the Registrant. 10-Q 001-37581 3.2 08/07/2023
    4.3 Certificate of Amendment to Amended and Restated Certificate of Incorporation of the Registrant. 8-K 001-37581 3.1 06/05/2025
    4.4 Amended and Restated Bylaws of the Registrant. 8-K 001-37581 3.1 06/24/2020
    4.5 Aclaris Therapeutics, Inc. 2025 Equity Incentive Plan. 8-K 001-37581 10.1 06/05/2025
    4.6 Form of Stock Option Grant Notice and Option Agreement used in connection with the Aclaris Therapeutics, Inc. 2025 Equity Incentive Plan. 8-K 001-37581 10.2 06/05/2025

     

    3

     

     

    4.7 Form of Restricted Stock Unit Grant Notice and Restricted Stock Unit Award Agreement used in connection with the Aclaris Therapeutics, Inc. 2025 Equity Incentive Plan. 8-K 001-37581 10.3 06/05/2025
    5.1* Opinion of Cooley LLP. – – – –
    23.1* Consent of Cooley LLP (included in Exhibit 5.1). – – – –
    23.2* Consent of Independent Registered Public Accounting Firm. – – – –
    24.1* Power of Attorney (included on the signature page of this Form S-8). – – – –
    107* Filing Fee Table – – – –

     

    * Filed herewith.

     

    Item 9. Undertakings.

     

    1.The undersigned registrant hereby undertakes:

     

    (a)           To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:

     

    (i)            To include any prospectus required by Section 10(a)(3) of the Securities Act of 1933, as amended (the “Securities Act”);

     

    (ii)           To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the “Calculation of Filing Fee Tables” in the effective registration statement; and

     

    (iii)          To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement;

     

    Provided, however, that paragraphs (a)(i) and (a)(ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the registrant pursuant to section 13 or section 15(d) of the Exchange Act that are incorporated by reference in the registration statement.

     

    (b)           That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered herein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (c)           To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

     

    4

     

     

    2.The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to section 15(d) of the Exchange Act) that is incorporated by reference in the Registration Statement shall be deemed to be a new registration statement relating to the securities offered herein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    3.Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

     

    5

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Wayne, Commonwealth of Pennsylvania, on this 5th day of June, 2025.

     

      Aclaris Therapeutics, Inc.
       
      By: /s/ Neal Walker
        Neal Walker
        Chief Executive Officer

     

    POWER OF ATTORNEY

     

    Know All Persons By These Presents, that each person whose signature appears below constitutes and appoints Neal Walker, Kevin Balthaser and Matthew Rothman, and each of them, as his or her true and lawful attorneys-in-fact and agents, each with the full power of substitution, for him or her and in their name, place or stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement on Form S-8, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or any of them, or his, her or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

     

    Signature   Title   Date
    /s/ Neal Walker   Chief Executive Officer and Director   June 5, 2025
    Neal Walker   (Principal Executive Officer)    
             
    /s/ Kevin Balthaser   Chief Financial Officer   June 5, 2025
    Kevin Balthaser   (Principal Financial Officer and Principal Accounting Officer)    
             
    /s/ Christopher Molineaux   Lead Independent Director   June 5, 2025
    Christopher Molineaux        
             
    /s/ Hugh Davis   President, Chief Operating Officer and Director   June 5, 2025
    Hugh Davis        
             
    /s/ Maxine Gowen   Director   June 5, 2025
    Maxine Gowen      
             
    /s/ William Humphries   Director   June 5, 2025
    William Humphries        
             
    /s/ Anand Mehra   Director   June 5, 2025
    Anand Mehra        
             
    /s/ Vincent Milano   Director   June 5, 2025
    Vincent Milano      
             
    /s/ Andrew Schiff   Director   June 5, 2025
    Andrew Schiff        

     

    6

     

    Get the next $ACRS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ACRS

    DatePrice TargetRatingAnalyst
    5/28/2025$8.00Outperform
    Wedbush
    3/18/2025Overweight
    Cantor Fitzgerald
    12/23/2024$20.00Neutral → Buy
    H.C. Wainwright
    11/20/2024Neutral → Overweight
    Cantor Fitzgerald
    11/19/2024$2.00 → $7.00Market Perform → Outperform
    Leerink Partners
    11/19/2024$8.00Neutral → Buy
    BTIG Research
    11/19/2024$2.00 → $7.00Hold → Buy
    Jefferies
    11/18/2024$3.00 → $13.00Neutral → Overweight
    Piper Sandler
    More analyst ratings

    $ACRS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Aclaris Therapeutics Inc.

      SC 13G - Aclaris Therapeutics, Inc. (0001557746) (Subject)

      11/25/24 11:02:19 AM ET
      $ACRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Aclaris Therapeutics Inc.

      SC 13G - Aclaris Therapeutics, Inc. (0001557746) (Subject)

      11/22/24 4:00:23 PM ET
      $ACRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Aclaris Therapeutics Inc.

      SC 13G - Aclaris Therapeutics, Inc. (0001557746) (Subject)

      11/21/24 4:51:50 PM ET
      $ACRS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACRS
    SEC Filings

    See more
    • SEC Form S-8 filed by Aclaris Therapeutics Inc.

      S-8 - Aclaris Therapeutics, Inc. (0001557746) (Filer)

      6/5/25 5:01:02 PM ET
      $ACRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aclaris Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - Aclaris Therapeutics, Inc. (0001557746) (Filer)

      6/5/25 4:01:51 PM ET
      $ACRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Aclaris Therapeutics Inc.

      SCHEDULE 13G/A - Aclaris Therapeutics, Inc. (0001557746) (Subject)

      5/15/25 10:45:24 AM ET
      $ACRS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACRS
    Leadership Updates

    Live Leadership Updates

    See more
    • Aclaris Therapeutics Appoints Jesse Hall, M.D. as Chief Medical Officer

      WAYNE, Pa., April 29, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that Jesse Hall, M.D. has been appointed as Chief Medical Officer. Dr. Hall's extensive medical and clinical development experience in areas including immunology and antibody development will be essential as he leads Aclaris' clinical strategy to fully leverage the opportunities in the Company's portfolio of immuno-inflammatory product candidates. "At Aclaris, our vision is to drive the leading edge of therapeutic innovation in I&I; Jesse shares this vision and

      4/29/25 7:00:32 AM ET
      $ACRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Flare Therapeutics Appoints Douglas Manion, M.D., FRCP (C) as Chief Executive Officer

      CAMBRIDGE, Mass., April 23, 2024 /PRNewswire/ -- Flare Therapeutics Inc., a clinical-stage biotechnology company targeting transcription factors to discover precision medicines for cancer and other diseases, today announced the appointment of Douglas Manion, M.D., FRCP (C), as Chief Executive Officer, effective immediately. Dr. Manion brings over two decades of experience in pharmaceutical research and development, having held leadership roles across several biotechnology and pharmaceutical companies. He succeeds interim CEO Abbie Celniker, Ph.D., a partner at Third Rock Ventures, who will continue to serve as Chair of the Company's Board of Directors.

      4/23/24 8:00:00 AM ET
      $ACRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aclaris Therapeutics Announces Key Leadership Transitions

      - Dr. Neal Walker to transition to Chair of the Board of Directors - Current Board Chair Christopher Molineaux to become Lead Independent Director - Douglas Manion, M.D. appointed to succeed Dr. Walker as Chief Executive Officer and appointed to the Board of Directors - Kevin Balthaser appointed Chief Financial Officer to succeed retiring Frank Ruffo - Matthew Rothman appointed General Counsel WAYNE, Pa., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced several key leadership changes. Effective January 1, 2023, co-founder

      11/22/22 4:01:00 PM ET
      $ACRS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACRS
    Financials

    Live finance-specific insights

    See more

    $ACRS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Aclaris Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

      - Multiple Catalysts in Immuno-Inflammatory Indications Anticipated in 2025 and 2026 - - Expected Cash Runway Extended Through the First Half of 2028 - - Phase 2 Results Received to Date from Chinese Partner CTTQ Provide Clinical Evidence of Enhanced Potency of Bosakitug (ATI-045) and Opportunity for Development Partnerships - - Investigational New Drug (IND) Application for Bispecific Antibody ATI-052 Cleared by U.S. Food and Drug Administration - WAYNE, Pa., May 08, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial res

      5/8/25 6:50:51 AM ET
      $ACRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aclaris Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update

      - Rich Catalyst Calendar Expected in 2025 Including Phase 2 Data in Multiple Immuno-Inflammatory Disease Indications - - Data from CTTQ's Phase 2 Studies of Bosakitug (ATI-045) in Chinese Patients with Severe Asthma and Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Expected in the First Half of 2025 to Inform Internal Development Programs - - Initiation of Enrollment in Phase 2b Trial for Bosakitug in Atopic Dermatitis (AD) on Track for the First Half of 2025 - - Cash Runway Expected into 2028 - WAYNE, Pa., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inf

      2/27/25 6:59:55 AM ET
      $ACRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aclaris Therapeutics Announces Exclusive, Global License Agreement with Biosion, Inc., adding Potential Best-in-Class Biologics Assets to Pipeline

      - Enhances Aclaris' pipeline with complementary biologics portfolio -- Expands leadership team with addition of seasoned biotech executives -- Management to host conference call today at 8:30 AM ET - WAYNE, Pa., Nov. 18, 2024 (GLOBE NEWSWIRE) --  Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that it has entered into an exclusive license agreement with Biosion, Inc. (Biosion) for worldwide rights (excluding Greater China) to BSI-045B, a potential best-in-class, clinical-stage, novel anti-TSLP monoclonal antibody, and BSI-502, a potential best-in-class, pre-cl

      11/18/24 8:10:04 AM ET
      $ACRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Mehra Anand bought $1,499,998 worth of shares (666,666 units at $2.25), increasing direct ownership by 1,537% to 710,030 units (SEC Form 4)

      4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)

      11/20/24 4:20:04 PM ET
      $ACRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Leonard Braden Michael bought $472,757 worth of shares (373,569 units at $1.27) (SEC Form 4)

      4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)

      8/5/24 3:57:34 PM ET
      $ACRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Leonard Braden Michael bought $359,010 worth of shares (273,730 units at $1.31) (SEC Form 4)

      4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)

      7/31/24 4:10:09 PM ET
      $ACRS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACRS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Aclaris Therapeutics Initiates Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis

      - Bosakitug is a Potential Best-in-Class Investigational Monoclonal Antibody with Demonstrated Superior Potency, Residence Time, and Affinity to Thymic Stromal Lymphopoietin (TSLP) - - Top Line Results Expected in the Second Half of 2026 - WAYNE, Pa., June 02, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that it has initiated a randomized, double-blind, placebo-controlled Phase 2 trial of bosakitug (ATI-045) in patients with moderate-to-severe atopic dermatitis (AD). "We are excited to initiate this Phase 2 trial following the

      6/2/25 6:59:53 AM ET
      $ACRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aclaris Therapeutics to Participate in Two June Healthcare Conferences

      WAYNE, Pa., May 28, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that the Company will participate in two upcoming healthcare conferences in June. On Wednesday June 4, 2025, at 10:30 AM EDT, Aclaris' Chief Executive Officer Dr. Neal Walker and other members of Aclaris' senior leadership team will participate in a fireside chat during Jefferies Global Healthcare Conference in New York, NY.On Wednesday June 11, 2025, at 1:20 PM EDT, Dr. Walker and other members of Aclaris' senior leadership team will participate in a fireside chat

      5/28/25 9:20:15 AM ET
      $ACRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aclaris Therapeutics to Participate in the HC Wainwright "HCW@Home" Series

      WAYNE, Pa., May 09, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that Aclaris' Chief Executive Officer Neal Walker and other members of the Aclaris senior leadership team will participate in a fireside chat during the virtual HC Wainwright "HCW@Home" series. The virtual fireside chat will take place on Friday May 16, 2025, at 1:00 PM EDT. A live and archived webcast of the event will be accessible on the Events page of https://www.aclaristx.com/. The webcast will be available on the Aclaris website for at least 30 days. About Ac

      5/9/25 7:00:19 AM ET
      $ACRS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACRS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Wedbush initiated coverage on Aclaris Therapeutics with a new price target

      Wedbush initiated coverage of Aclaris Therapeutics with a rating of Outperform and set a new price target of $8.00

      5/28/25 8:54:54 AM ET
      $ACRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cantor Fitzgerald resumed coverage on Aclaris Therapeutics

      Cantor Fitzgerald resumed coverage of Aclaris Therapeutics with a rating of Overweight

      3/18/25 8:23:58 AM ET
      $ACRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aclaris Therapeutics upgraded by H.C. Wainwright with a new price target

      H.C. Wainwright upgraded Aclaris Therapeutics from Neutral to Buy and set a new price target of $20.00

      12/23/24 7:21:33 AM ET
      $ACRS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACRS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Medical Officer Hall Jesse Wayne

      4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)

      5/5/25 4:32:56 PM ET
      $ACRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Hall Jesse Wayne

      3 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)

      5/5/25 4:29:44 PM ET
      $ACRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CEO Walker Neal converted options into 9,467 shares and covered exercise/tax liability with 2,975 shares, increasing direct ownership by 0.44% to 1,479,824 units (SEC Form 4)

      4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)

      5/5/25 4:20:04 PM ET
      $ACRS
      Biotechnology: Pharmaceutical Preparations
      Health Care